1,659 research outputs found
Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer
The feasibility and effectiveness of a combined chemoradiotherapy treatment modality for locally advanced head and neck cancer was tested in a phase II trial. From March 1995 to June 1998, 35 patients with advanced squamous cell carcinoma of the head and neck were treated with a continuous intravenous infusion of 5-fluorouracil (600 mg m(-2) 24 h(-1) for Days 1 to 5 (120 h)) and mitomycin-C (10 mg m(-2) intravenously) on Day 5 during the first week of radiotherapy and on Day 36. 31 patients had stage IV disease; 4 patients had stage Ill. and 1 patient had stage II. Patient ages ranged from 42-69 years (median 56.7 years). The tumours involved were as follows: oral cavity (n=11); oropharynx (n=14); hypopharynx/larynx (n=10). Radiotherapy was delivered to a total dose of 70 Gy with conventional fractionation (1 Gy per fraction, five times a week). Chemotherapy was well tolerated and all patients received the intended dose. Mild nausea occurred in five patients. After a mean follow-up of 21 months (range 10-44 months), 8 (23%) patients remain alive. A complete response was seen in 28 (80%) patients. When a recurrence appeared, it was within the first year after treatment. 1- and 2-year overall survival rates were 46% and 23%, respectively. Grade 3 mucositis occurred in 17% of patients. Grade 1-2 thrombopaenia occurred in 3 (9%) patients, grade >2 leukopaenia in 4(11%) patients. and grade greater than or equal to2 anaemia in 3 (9%) patients. We observed a treatment interruption of maximum 1 week for six patients owing to mucositis. Febrile neutropaenia or aplasia were not observed. The concomitant use of 5-fluorouracil, mitomycin-C and radiotherapy in locally advanced head and neck carcinoma is well tolerated in this group of patients. This protocol showed good locoregional response with a very low toxicity profile
Jean-Marie Pradier : La Scène et la Fabrique des corps. Ethnoscénologie du spectacle (5e siècle av. J.-C.-18e siècle), 2000
L'Aminot Tanguy. Jean-Marie Pradier : La Scène et la Fabrique des corps. Ethnoscénologie du spectacle (5e siècle av. J.-C.-18e siècle), 2000. In: Dix-huitième Siècle, n°33, 2001. L'Atlantique, sous la direction de Marcel Dorigny . pp. 706-707
In regards to: Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous cell carcinoma of the head and neck by Pradier et al. (Int J Radiat Oncol Biol Phys 2005;63 : 1368-1377) - In reply to Drs. Cengiz Et Al.
L'âne de Suzanne : historiette / paroles de C. Pradier ; musique de Paul Blaquière
Chansons françaises -- +* 1800......- 1899......+:19e siècle
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C
Background. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5-fluorouracil (5-FU) and mitomycin-C infusion in inoperable head and neck cancer. Methods. Seventy-six patients (86% men, 14% women), mean age 57 years, with primary inoperable head and neck cancer were treated with 70 Gy plus simultaneous intravenous chemotherapy with 5-FU (600 mg/m(2)/d, days 1 to 5) and mitomycin-C (10 mg/m(2), day 5 plus 36). Results. After a mean follow-up of 13 months, 31 patients were alive. Complete response (CR) was seen in 63%. The 1- and 2-year overall survival rates were 67.7% and 39.5%, and locoregional control rates were 51.7% and 35.6%. Pretreatment hemoglobin <13.9 g/dL was associated with lower locoregional control rates (p = .03). Therapy was well tolerated (grade 3 mucositis in 21%, grade 4 in 1%, grade 3 leukopenia in 11%). Conclusions. Our radiochemotherapy regimen offers a curative option for this group of patients with a poor prognosis. Hemoglobin levels before therapy have an influence on prognosis. (C) 2004 Wiley Periodicals, Inc
Interindividual variations in positioning accuracy and patient motion during pelvic radiotherapy
Adjuvant radiotherapy after transoral microlasersurgery for advanced primary squamous cell carcinoma of the head and neck
Pelvic and paraaortal radiotherapy with concurrent cisplatin chemotherapy for high risk cervical cancer
- …
